Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Anti-inflammatory activity of lisinopril in albino rats

Siddamma Amoghimath, Suresha R N.




Abstract

Background: Angiotensin II (Ang II) is a product of renin angiotensin aldosterone system. Angiotensin‑II regulates vascular tone, stimulates the release of pro‑inflammatory cytokines, activates nuclear factor‑kappa B, increases oxidant stress and functions as an inflammatory molecule. Lisinopril an angiotensin converting enzyme (ACE) inhibitor act by inhibiting ACE, decreases angiotensinogen II activity. Hence the present was to evaluate the anti-inflammatory activity of lisinopril.

Aims and Objectives: To evaluate the anti-inflammatory activity of lisinopril in albino rats.

Materials and Methods: Eighteen Wistar albino rats weighing around 150–200 g of either sex were randomly selected from central animal facility and divided into three groups. The control group received normal saline 25 ml/kg, standard group received indomethacin 10 mg/kg and test group received lisinopril (3.6 mg/kg) orally for 6 days. The animals were subjected to carrageenan induced paw oedema and cotton pellet induced granuloma model.

Results: Lisinopril significantly decreased the mean paw oedema in carrageenan induced paw oedema when compared to control and in cotton pellet induced granuloma lisinopril decreased the mean granuloma weight when compared to control.

Conclusion: Lisinopril showed anti-inflammatory activity when given for 6 consecutive days per orally in albino rats in carrageenan induced paw oedema and cotton pellet induced granuloma model.

Key words: Angiotensin II; Carrageenan; Cotton Pellet; Nuclear Factor‑kappa B; Reactive Oxygen Species






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.